Silence Therapeutics plc

NASDAQ
SLN
paper.types.company
Rentabilité sur six mois: -34.94%
Rendement en dividendes: 0%
Secteur: Healthcare

4.99 $

-0.01 $ -0.2%
2.18 $
21.74 $

paper.min_max_per_year

Calendrier des promotions Silence Therapeutics plc

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

plus de détails
The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2020-09-08
ISIN
US82686Q1013
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
gbp
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 7.51 1
P/BV 2.42 6
P/E 0 0
Efficacité
Nom Signification Grade
ROA -28.13 0
ROE -58.19 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0024 10
Debt/Ratio 0.000576 10
Debt/Equity 0.5115 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 487.7 10
Rentabilité Ebitda, % 3.63 1
Rentabilité EPS, % 27.42 4
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 5 $ 0 $ 0 $ -0.2 % 0 % 0 %
common.calendar.number_days.7d 5.14 $ 0 $ 0 $ -2.92 % 0 % 0 %
common.calendar.number_days.30d 3.5 $ 3.83 $ 5.14 $ 42.57 % 0 % 0 %
common.calendar.number_days.90d 4.77 $ 2.18 $ 5.14 $ 4.61 % 0 % 0 %
common.calendar.number_days.180d 7.67 $ 2.18 $ 7.41 $ -34.94 % 0 % 0 %
common.calendar.number_days.1y 21.81 $ 2.18 $ 21.74 $ -77.12 % 0 % 0 %
common.calendar.number_days.3y 10.45 $ 2.18 $ 26.25 $ -52.25 % 0 % 0 %
common.calendar.number_days.5y 0 $ 2.18 $ 28.35 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 2.18 $ 28.35 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 6.88 $ 2.18 $ 7.41 $ -27.47 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Craig A. Tooman M.B.A. President, CEO & Executive Director 1.49M 1965 (60 années)
Ms. Rhonda L. Hellums Executive VP, CFO & Secretary 907.23k 1972 (53 année)
Dr. Steven J. Romano M.D. Executive VP and Chief Research & Development Officer 662.65k 1959 (66 années)
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer N/A
Ms. Gem Gokmen Hopkins Head of IR & Corporate Communications N/A
Dr. Barbara A. Ruskin J.D., Ph.D. Senior VP and Chief Intellectual Property & Innovation Officer N/A 1960 (65 années)
Dr. Eric Floyd M.B.A., M.S., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance N/A 1963 (62 année)
Mr. J.P. Gabriel Chief Technical Operations Officer N/A
Mr. Curtis Rambaran M.D. Chief Medical Officer N/A
Ms. Gianine Esposito Chief Human Resources Officer

Informations sur l'entreprise

Adresse: United Kingdom, London, 72 Hammersmith Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.silence-therapeutics.com